VENTYX BIOSCIENCES
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
VENTYX BIOSCIENCES
Industry:
Biopharma Biotechnology
Founded:
2018-01-01
Address:
Encinitas, California, United States
Country:
United States
Website Url:
http://www.ventyxbio.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
165 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Selecta Biosciences
Selecta Biosciences is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
RTW Investments LLC
RTW Investments LLC investment in Series B - Ventyx Biosciences
Third Point
Third Point investment in Series B - Ventyx Biosciences
Farallon Capital Management
Farallon Capital Management investment in Series B - Ventyx Biosciences
venBio Partners
venBio Partners investment in Series B - Ventyx Biosciences
Wellington Management
Wellington Management investment in Series B - Ventyx Biosciences
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Ventyx Biosciences
OrbiMed
OrbiMed investment in Series B - Ventyx Biosciences
Qiming Venture Partners USA
Qiming Venture Partners USA investment in Series B - Ventyx Biosciences
Surveyor Capital
Surveyor Capital investment in Series B - Ventyx Biosciences
Logos Capital
Logos Capital investment in Series B - Ventyx Biosciences
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-09 | Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer |
Official Site Inspections
http://www.ventyxbio.com Semrush global rank: 2.22 M Semrush visits lastest month: 8.76 K
- Host name: 151.101.66.159
- IP address: 151.101.66.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ventyx Biosciences" on Search Engine
Ventyx Biosciences - Crunchbase Company Profile & Funding
About. Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders. Encinitas, California, United …See details»
Ventyx Biosciences - Funding, Financials, Valuation & Investors
Funding. Ventyx Biosciences has raised a total of. $441.6M. in funding over 4 rounds. Their latest funding was raised on Mar 7, 2024 from a Post-IPO Equity round. Ventyx …See details»
New Science Ventures Portfolio Company Ventyx Biosciences …
Mar 9, 2021 Ventyx Biosciences, Inc. is a clinical-stage biotechnology company advancing a broad pipeline of potent and selective small-molecule drug candidates to …See details»
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor ...
Mar 11, 2024 Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event. VTX3232 was well-tolerated in …See details»
Ventyx Biosciences Announces Positive Topline Phase 1 Data for …
ENCINITAS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a multi-asset, clinical-stage biopharmaceutical company …See details»
Ventyx Biosciences Announces Positive Results from the Phase …
SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing …See details»
Ventyx Biosciences to Present Results of the Phase 2 Trial
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing …See details»
Ventyx Biosciences - Updates, News, Events, Signals & Triggers
Mar 1, 2024 Ventyx Biosciences, a clinical-stage biopharmaceutical company, announced a $100 million private placement of common stock and plans to initiate …See details»
Ventyx Biosciences Announces Pricing of Upsized Initial Public …
ENCINITAS, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing new …See details»
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor ...
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing …See details»
Ventyx Biosciences Readies $125 Million IPO - Seeking Alpha
Oct 18, 2021 Ventyx Biosciences has filed to raise $125 million in an IPO. The firm is developing treatment candidates for autoimmune and inflammatory diseases. VTYX is …See details»
Ventyx Biosciences to Present Results of the Phase 2 Trial of …
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing …See details»
Ventyx Biosciences | CipherBio
Biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. Stage: Public. Total …See details»
Ventyx Biosciences - Contacts, Employees, Board Members
Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.See details»
Ventyx Biosciences to Present Results of the Phase 2
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing …See details»
Contact Us – Ventyx Biosciences
Contact Us. [email protected]; Ventyx Biosciences, Inc. 662 Encinitas Boulevard, Suite 250 Encinitas, CA 92024See details»